Key Highlights

  • Kura Oncology (NASDAQ:KURA) appears on the aggressive small cap screen with a one-year EPS change of 32.93% and a Market Value of about USD 689 million, at USD 7.51 in the November 13 snapshot.
  • Third quarter Komzifti net product Revenue reached USD 13.9 million, up 53% from the second quarter, with about 150 new patient starts and more than 420 prescriptions.
  • The net loss narrowed to USD 70.2 million, or USD 0.78 per share, from USD 74.1 million, or USD 0.85, which is the source of the screen's EPS improvement.
  • Cash and investments of USD 492.1 million are expected to fund operations beyond initial Phase 3 KOMET-017 results in 2028, with USD 180 million of potential partner milestones.

An Early Launch Gaining Traction

Kura reported on November 10, and the main story is the launch of Komzifti, its menin inhibitor ziftomenib, for relapsed or refractory acute myeloid leukemia with an NPM1 mutation. Net product revenue was USD 13.9 million in the third quarter, up 53% from the second quarter, and nine-month sales reached USD 28.8 million. New patient starts rose about 30% sequentially to around 150, and total prescriptions rose about 65% to more than 420. The company says it holds the majority share of new patient starts among menin inhibitors in this setting, a competitive market where another approved drug is already in use. Collaboration revenue from its partner Kyowa Kirin was USD 8.9 million against USD 20.8 million a year earlier, bringing total revenue to about USD 22.8 million. Expenses were stable, with research spending of USD 66.9 million and selling and administrative costs of USD 30.2 million.

Losses, Cash and Financing

The screen's one-year EPS change of 32.93% reflects a narrower loss rather than profit. The net loss was USD 70.2 million, or USD 0.78 per share, against USD 74.1 million, or USD 0.85, a year earlier, though the nine-month loss widened to USD 211.9 million. Cash, equivalents and short-term investments fell to USD 492.1 million at September 30 from USD 667.2 million at the end of 2025, a burn of roughly USD 58 million per quarter. Kura has added flexible funding. A financing arrangement with Oberland Capital provides up to USD 300 million, of which USD 55 million was received at closing, carrying interest of 6.95% to 8.95% and a single digit Royalty on US Komzifti sales capped at 20% of principal advanced. The company expects anticipated Kyowa Kirin milestone payments of USD 180 million and collaboration revenue of USD 40 million to USD 45 million in 2026, rising to USD 90 million to USD 110 million in each of 2027 and 2028.

Catalysts and Risks

The next catalyst is the American Society of Hematology meeting on December 12 to 15, where Kura will present eight ziftomenib abstracts, including two oral presentations on combinations with FLT3 inhibitors in the KOMET-007 and KOMET-008 studies. Expanding into front-line and combination settings is the route to a much larger market, and the Phase 3 KOMET-017 trial is the key long-term readout. The shares fell about 23% on November 4 when the abstracts were released, suggesting investors found the early data less compelling than hoped. Kura is also building optionality outside oncology. It spun out Caspian Therapeutics with USD 50 million of outside funding to develop a diabetes candidate, keeping roughly half the ownership, and it plans a registrational study of darlifarnib in a salivary gland cancer starting in the first half of 2027. A new chief financial officer joined in September.

Where Things Stand

Kura Oncology (NASDAQ:KURA) is in the early, cash consuming phase of a cancer drug launch, with Komzifti sales rising quickly from a small base. The screen's EPS gain reflects a narrower loss. Cash of USD 492.1 million and partner funding give runway, while December ASH data will shape sentiment.